Atezolizumab plus bevacizumab in advanced hepatocellular carcinoma after treatment failure with multikinase inhibitors.

Date publication

avril 2023

Journal

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre , Pr MANFREDI Sylvain

Tous les auteurs :
Haghnejad V, Muller M, Blaise L, Gerolami R, Bouattour M, Assenat E, Manfredi S, Peron JM, Burcheri-Curatolo A, Lopez A, Ressiot E, Nahon P, Bronowicki JP

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/37019737

Résumé

Data on the effectiveness of atezolizumab plus bevacizumab (atezo-bev) after failure of multikinase inhibitor (MKI) therapy in patients with advanced hepatocellular carcinoma are scarce.

Mots clés

Atezolizumab plus bevacizumab, Hepatocellular carcinoma, Liver cancer, Tyrosine kinase inhibitors

Référence

Dig Liver Dis. 2023 04 3;: